Abbott (ABT) Stock May Be 28% Undervalued Following Amulet 360 Trial Results
Alpha Vantage · Simply Wall St · · AI-summarised by FinFlash
Abbott Laboratories' stock (ABT) may be significantly undervalued by 28% according to a Discounted Cash Flow (DCF) analysis, which projects strong future cash flow growth driven by new medical devices like Amulet 360, SonicForce, and the Cephea Mitral Valve System. The company's pipeline in diabetes and neurostimulation also supports these expectations.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.